Basilea Pharmaceutica AG Statistics
Total Valuation
Basilea Pharmaceutica AG has a market cap or net worth of CHF 552.12 million. The enterprise value is 601.60 million.
Market Cap | 552.12M |
Enterprise Value | 601.60M |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
Earnings Date | Nov 13, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Basilea Pharmaceutica AG has 12.12 million shares outstanding. The number of shares has decreased by -17.17% in one year.
Shares Outstanding | 12.12M |
Shares Change (YoY) | -17.17% |
Shares Change (QoQ) | -43.09% |
Owned by Insiders (%) | 3.05% |
Owned by Institutions (%) | 36.50% |
Float | 11.75M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 14.47 |
PS Ratio | 3.68 |
PB Ratio | 32.89 |
P/FCF Ratio | 59.14 |
PEG Ratio | 0.51 |
Enterprise Valuation
EV / Earnings | -922.70 |
EV / Sales | 4.04 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | 64.45 |
Financial Position
The company has a current ratio of 4.10, with a Debt / Equity ratio of 669.89.
Current Ratio | 4.10 |
Quick Ratio | 2.96 |
Debt / Equity | 669.89 |
Debt / EBITDA | n/a |
Debt / FCF | 12.05 |
Interest Coverage | -0.87 |
Financial Efficiency
Return on equity (ROE) is -4.10% and return on invested capital (ROIC) is -2.73%.
Return on Equity (ROE) | -4.10% |
Return on Assets (ROA) | -2.05% |
Return on Capital (ROIC) | -2.73% |
Revenue Per Employee | 955,269 |
Profits Per Employee | -4,179 |
Employee Count | 147 |
Asset Turnover | 0.71 |
Inventory Turnover | 4.38 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.64% in the last 52 weeks. The beta is 0.70, so Basilea Pharmaceutica AG's price volatility has been lower than the market average.
Beta (5Y) | 0.70 |
52-Week Price Change | -4.64% |
50-Day Moving Average | 41.33 |
200-Day Moving Average | 38.71 |
Relative Strength Index (RSI) | 63.88 |
Average Volume (20 Days) | 43,656 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Basilea Pharmaceutica AG had revenue of CHF 149.02 million and -652,000 in losses. Loss per share was -0.05.
Revenue | 149.02M |
Gross Profit | 24.12M |
Operating Income | -6.86M |
Pretax Income | -14.08M |
Net Income | -652,000 |
EBITDA | -5.60M |
EBIT | -6.86M |
Loss Per Share | -0.05 |
Balance Sheet
The company has 62.96 million in cash and 112.45 million in debt, giving a net cash position of -49.48 million or -4.08 per share.
Cash & Cash Equivalents | 62.96M |
Total Debt | 112.45M |
Net Cash | -49.48M |
Net Cash Per Share | -4.08 |
Equity (Book Value) | 16.79M |
Book Value Per Share | 1.38 |
Working Capital | 117.23M |
Cash Flow
In the last 12 months, operating cash flow was 10.30 million and capital expenditures -966,000, giving a free cash flow of 9.34 million.
Operating Cash Flow | 10.30M |
Capital Expenditures | -966,000 |
Free Cash Flow | 9.34M |
FCF Per Share | 0.77 |
Margins
Gross margin is 16.19%, with operating and profit margins of -4.60% and -0.44%.
Gross Margin | 16.19% |
Operating Margin | -4.60% |
Pretax Margin | -9.45% |
Profit Margin | -0.44% |
EBITDA Margin | -3.76% |
EBIT Margin | -4.60% |
FCF Margin | 6.26% |
Dividends & Yields
Basilea Pharmaceutica AG does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 17.17% |
Shareholder Yield | 17.17% |
Earnings Yield | -0.12% |
FCF Yield | 1.69% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |